Table 3.
OR with 95% CI of developing MS among subjects categorized by EBNA1 status and smoking, stratified by age at EBV assessment.
| EBNA-1 IgG | Smoking | EBV assessment at age < 50 years | EBV assessment at age ≥ 50 years | ||||
|---|---|---|---|---|---|---|---|
| ca/coa | OR (95% CI)b | OR (95% CI)c | ca/coa | OR (95% CI)b | OR (95% CI)c | ||
| Low | Never | 387/1045 | 1.0 (reference) | 1.0 (reference) | 302/611 | 1.0 (reference) | 1.0 (reference) |
| Low | Current | 223/387 | 1.6 (1.3–1.9) | 1.6 (1.3–2.0) | 282/427 | 1.3 (1.1–1.6) | 1.4 (1.1–1.7) |
| High | Never | 1227/1005 | 3.3 (2.9–3.8) | 3.0 (2.5–3.4) | 858/637 | 2.7 (2.3–3.2) | 2.4 (2.0–2.8) |
| High | Current | 836/426 | 5.3 (4.5–6.3) | 4.6 (3.9–5.5) | 984/461 | 4.3 (3.6–5.1) | 3.9 (3.2–4.7) |
| AP 0.3 (0.1–0.4) | AP 0.3 (0.2–0.4) | ||||||
AP with 95% CI between high EBNA1 IgG and smoking.
aNumber of exposed cases and controls
bAdjusted for age, sex, residential area, study, and ancestry
cAdjusted for age, sex, residential area, study, ancestry, infectious mononucleosis, adolescent body mass index, DRB1*1501, DRB1*0301, DRB1*1303, DRB1*0801, A*0201, B*4402, B*3801, B*5501, DQA1*0101, DQB1*0302, DQB1*0301, homozygote correction for DRB1*1501, DRB1*0301, and A*0201.